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Abstract  
Amorphous magnesium-substituted calcium phosphate (AMCP) nanoparticles (75-150 nm) 
form constitutively in large numbers in the mammalian gut. Collective evidence indicates that 
they trap and deliver luminal macromolecules to mucosal antigen presenting cells (APCs) and 
facilitate gut immune homeostasis. Here, we report on a synthetic mimetic of the endogenous 
AMCP and show that it has marked capacity to trap macromolecules during formation. 
Macromolecular capture into AMCP involved incorporation as shown by STEM tomography 
of the synthetic AMCP particle with 5 nm ultra-fine iron (III) oxohydroxide. In vitro, organic 
cargo-loaded synthetic AMCP was taken up by APCs and tracked to lysosomal 
compartments. The AMCP itself did not regulate any gene, or modify any gene regulation by 
its cargo, based upon whole genome transcriptomic analyses. We conclude that synthetic 
AMCP can efficiently trap macromolecules and deliver them to APCs in a silent fashion, and 
may thus represent a new platform for antigen delivery.  
Key words: Amorphous magnesium-substituted calcium phosphate, nanoparticles, 
peptidoglycan, PD-L1 
 
Abbreviations: ACP: amorphous calcium phosphate; AMCP: amorphous magnesium-
substituted calcium phosphate; APC: antigen presenting cell; BSA: bovine serum albumin; 
Pg: peptidoglycan; LPS: lipopolysaccharides. TEM: transmission electron microscopy. 
HAADF: high-angle annular dark-field.  STEM: scanning transmission electron microscopy. 
ICP-OES: inductively coupled plasma – optical emission spectrometry. TCM: tissue culture 
medium. 
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Background 
Bio-mineralisation is a well conserved physiological phenomenon that occurs in most life 
forms (bacteria, diatoms, plants, animals and humans)
1-5
 and is usually restricted to 
specialised tissues (e.g. bone, teeth and otoconia) for the formation of calcium-based 
minerals. In mammals, calcium phosphates are major biominerals and, depending on the 
tissues involved, may vary in structure from amorphous calcium phosphate (ACP) to fully 
crystalline forms (i.e. apatite). Due to its low toxicity but ready turnover, potential therapeutic 
roles for ACP are multiple, ranging from  bio-materials
6
, such as in dentistry
7
, through to 
drug delivery
8-9
, such as in vaccination
10
. However, ACP is notoriously unstable and its in 
vivo ‘lifetime’ is determined not only by environmental factors such as pH, viscosity, ionic 
strength and temperature 
11-13
 but also by its own structure, especially the incorporation of 
other ions or molecules (for e.g. fetuin). Boskey & Posner 
14
 studied the kinetics of ACP 
conversion and found that substitution of Ca ions in ACP by Mg ions leads to greater stability 
of the amorphous state, a finding which has since been confirmed by others
15-16
. Interestingly, 
we reported that in the human and murine gastrointestinal tract, there is extensive constitutive 
(i.e. natural, physiological) formation of porous amorphous magnesium-substituted calcium 
phosphate (AMCP) nanoparticles, typically 75-150 nm in diameter 
17
. These luminally-
formed AMCP nanominerals are found co-associated with macromolecules such as bacterial 
peptidoglycan and dietary protein in mucosal antigen presenting cells (APCs) 
17
.  
These findings with endogenous AMCP imply that the particles form in the gut lumen, 
trapping luminal macromolecules in the process, and then chaperone their cargo to 
specialised APCs thereby facilitating cross-talk between the lumen and intestinal tissue 
17
. 
The physiological and biological relevance of this constitutive self-assembly of nanoparticles 
and their ‘cargo shuttling’ function is currently not fully understood but generation of this 
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knowledge would be greatly facilitated by the synthesis of in vitro counterparts such that their 
properties can be scrutinised. 
Here we therefore set out to reproduce the exact form of these entities and, in particular, to 
test whether the presence of macromolecules (e.g., proteins and bacterial antigens) and ions 
(e.g., magnesium) would affect the phase, structural properties and stability of the resulting 
amorphous calcium phosphates. Under carefully controlled conditions, we demonstrated that 
the synthetic mimetics of the endogenous gastrointestinal nanomineral generated amorphous 
magnesium-substituted calcium phosphate nanoparticles (synthetic AMCP) of the right size 
and phase with versatile macromolecule-incorporation properties similar to their in vivo 
counterparts. We next considered synthetic AMCP interactions with immune cells both at the 
gene and protein level. Particularly, we observed that cargo-containing AMCP nanoparticles 
were readily taken up by peripheral blood antigen presenting cells, trafficked to lysosomal 
compartments and delivered their cargo in a ‘silent’ fashion. The synthetic mimetics of the 
AMCP nanomineral, as described herein, may therefore have valuable properties in drug 
delivery given that the material does not appear to influence outcomes as may be expected 
with conventional particle-cargo targeting of cells 
18
. 
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Methods 
Synthesis of mimetics of endogenous calcium phosphate with organic and inorganic 
macromolecules  
Synthetic AMCP particles were prepared using a modified protocol of Boskey and Posner 
14
. 
The modification consisted of the addition of extra magnesium and protein (bovine serum 
albumin, BSA) to enhance phase stability and precipitation in the presence or absence of, 
mainly, the microbial associated molecular pattern peptidoglycan (Pg) to mimic in vivo 
organic (bacterial) intestinal components. Exact protocols for each of the combinations 
investigated are given in the supplementary methods (Appendix A). 
Physico-chemical characterisation of synthetic AMCP particles 
Size measurement and structural morphology 
Following synthesis, hydrodynamic sizes of the AMCP particles were investigated by 
nanoparticle tracking analysis while structural morphology was addressed by transmission 
electron microscopy (TEM). 3D Structural morphology was further investigated using 
tomography experiments based on high-angle annular dark-field (HAADF) imaging in the 
scanning transmission electron microscopy (STEM) mode. 
Elemental composition 
Synthetic AMCP particles were dissolved in 5 % HNO3 (Sigma-Aldrich Company Ltd., 
Dorset, UK) prior to inductively coupled plasma – optical emission spectrometry (ICP-OES) 
analysis. Samples were analysed using the JY2000 ICP-OES (Horiba Jobin Yvon Ltd., 
Stanmore, UK) and Ca and P signals were detected at 396.847 nm and 177.440 nm, 
respectively. Quantification was performed using external standards (Calibration Standard 
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Solutions 1000 ppm, Fisher Scientific UK Ltd, Leicestershire, UK; 0.5-50 ppm).  Total Ca 
and P were obtained from particle suspensions collected after synthesis or after dilution in 
tissue culture medium (TCM). Background correction was performed using the Ca and P 
values obtained from D10 (i.e. the TCM) that had been subjected to the same treatment as 
particle suspensions. The Ca/P molar ratio of particle suspensions was calculated as: Ca/P = 
[
𝐶𝐶𝑎/𝐴𝑊𝐶𝑎
𝐶𝑃/𝐴𝑊𝑃
] where Cx is the background-corrected concentration of the respective element as 
measured by ICP-OES and AWx the atomic weight (i.e., 40.08 for Ca and 30.97 for P). 
Determination of zeta potential 
Electrophoretic mobility measurements of particle suspensions were performed by phase 
analysis light scattering on a Zetasizer Nano ZS (Malvern, Worcestershire, UK). 
Electrophoretic mobility of particles, in an applied field of 8.15 V/cm (effective voltage 49.7 
V; electrode spacing 6.1 cm), was then converted into zeta potentials by Dispersion 
Technology Software 4.20 using Henry’s equation and the Smoluchowski approximation for 
aqueous media. Measurements were taken as technical triplicates, and data are shown as 
mean of three to five independent experiments. 
Computational Modelling 
Small precursor calcium phosphate clusters, representative of the early stages of particle 
nucleation, were constructed and simulated. Posner’s cluster19, (Ca9(PO4)6), is considered to 
be the primary particle of amorphous calcium phosphate and the precursor to the formation of 
crystalline apatite. This cluster structure was therefore used for the initial model construction, 
but further modified by the removal of one calcium ion and the addition of two hydrogen ions 
(for charge compensation) to reflect the experimentally measured mimetic composition as 
obtained through X-ray microanalysis. Analysis of the clusters’ geometric structure and 
stability under magnesium ion substitution (for calcium ions) in all possible configurations 
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was carried out. The thermodynamic stability was assessed, using formation energy analysis. 
The formation energy of a single Mg substitution into a calcium phosphate cluster is given by 
Equation 1. 
𝐸𝑓 = 𝐸𝐴𝑀𝐶𝑃 − (𝐸𝐴𝐶𝑃 + 𝜇𝑀𝑔 − 𝜇𝐶𝑎)           Eq. 1 
where 𝐸𝐴𝑀𝐶𝑃 is the energy of the Mg-substituted cluster, 𝐸𝐴𝐶𝑃 is the energy of the cluster 
prior to Mg-substitution, 𝜇𝑀𝑔 is the chemical potential of magnesium and 𝜇𝐶𝑎 is the chemical 
potential of calcium. Chemical potentials for Mg and Ca were calculated from the lowest 
energy sources and sinks, namely magnesium and calcium metal respectively.  
Geometry optimization of the AMCP clusters was carried out using the plane-wave density 
functional theory code, CASTEP
20
. Convergence testing assigned a kinetic energy cut-off of 
430 eV and sampling of the Brillouin zone was carried out at the gamma point
21
 with the 
clusters placed centrally in a 20Å
3 
simulation cell. Ultrasoft pseudopotentials were 
employed
22
 along with the generalized gradient approximation (GGA) and PBE exchange-
correlation functional
23
. Convergence tolerances for energy change, maximum displacement 
and maximum force were set at 1×10
-5
 eV atom
-1
, 0.001 Å, and 0.03 eV Å
-1
 respectively. The 
simulation cell lattice parameters remained constrained throughout. For the substitution of 
Mg into hydroxyapatite, the lattice parameters were not constrained. Additionally, a 
maximum stress tolerance of 0.05 GPa and a 3x3x3 k-point grid for sampling of the Brillouin 
zone were employed.  
Macromolecule trapping properties of synthetic AMCP 
AMCP-trapping of macromolecules were assessed by determining the content of BSA and Pg 
from re-dissolved nanoparticles using protein and periodic acid schiff assays, while 
incorporation was demonstrated by STEM tomographic reconstruction of synthetic AMCP 
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containing electron dense material, namely ultra-fine iron (III) oxohydroxide
24
. Detailed 
methodology can be found in Appendix A, supplementary Methods. 
Biological properties of synthetic AMCP 
Studies with primary human cells and experimental protocols were approved by the research 
ethics committees of Cambridge, UK (reference 03/296) and carried out in accordance with 
approved guidelines. The biological properties of ACMP nanoparticles were examined in 
peripheral blood mononuclear cells, enriched monocytes and/or THP-1 as stated. AMCP 
nanoparticle uptake and lysosomal co-localisation were assessed by flow imaging techniques 
while AMCP-induced biological responses were investigated by looking at ‘toxicity’, 
‘inflammasome activation’, IL-1β responses and whole genome transcriptomic analyses. Full 
methods are given in Appendix A, supplementary Methods. 
Statistics 
Significant differences in experiments looking at the inflammasome activation were assessed 
by a two way ANOVA and Bonferroni's multiple comparisons test while experiments looking 
at cellular uptake, cell viability and surface PD-L1 expression were evaluated using 2 tailed 
paired t tests. Significance was set as p < 0.05. For transcriptomic studies, significant 
differences in expression were assessed using paired Intensity-Based Moderated T-statistic 
(IBMT) 
25
. Genes were defined as significantly changed when the p value was < 0.01. 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
11 
 
Results 
Physico-chemical and structural properties  
Following a screen of numerous candidate synthetic methods, we found that co-precipitation 
of a model protein (bovine serum albumin; BSA) at 500 μg/ml with 17.5 mM Ca2+, 19.5 mM 
phosphate and 3.6 mM Mg
2+
 in pH 8 aqueous buffer enabled the recovery of a precipitate 
that, when washed and re-suspended in tissue culture medium, consisted of disperse AMCP 
nanoparticles with a hydrodynamic size distribution (D10-D90) from ~50-215 nm, a D50 of ~ 
100 nm and a peak size at about 70 nm (Figure 1 and Table S1). Once re-suspended in tissue 
culture medium, the particle size, measured by nanoparticle tracking analysis, remained 
stable for at least 3 hours (Figure 1 and Table 1). The additional presence of peptidoglycan 
(50 μg) during co-precipitation did not impact these findings (Figure 1 and Table 1).  
Morphologically, agglomerates of non-facetted, micro-porous particles were evident and 
these were shown to be amorphous by TEM, whether pre-incubated or not in tissue culture 
medium (Figure 1, C-D and Figure 2, A). To ensure that the optimal synthetic composition 
had been attained, first principles Density Functional Theory (DFT) modelling of an 
amorphous calcium phosphate cluster model (Figure 1, E) based on the anticipated primary 
particle, which is termed ‘Posner’s Cluster’19, was undertaken. Prior to undergoing geometry 
optimization, the initial ‘Posner’s Cluster’ composition was modified to reflect the X-ray 
microanalysis results of the larger particles presented in Figure 2, B, with a reduction in Ca 
ion concentration and the addition of two H ions for charge compensation.  Simulations 
showed that Mg was most favourable in the central cation position of the cluster. This 
optimized model was then used to interrogate the stability of AMCP with differing Mg 
(substituting for Ca) concentrations. As previously reported for bulk phase amorphous 
calcium phosphate
 7, 11, 14 
the presence of both Mg
2+
 ions and protein stabilised the amorphous 
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nanoparticles and retarded/prevented conversion to crystalline calcium phosphate (Figure 
S1). However, formation energy analysis, which quantitatively assesses the thermodynamic 
stability of an elemental or molecular substitution in a structure, clearly showed that 
concentrations of Mg greater than that of our mimetic were thermodynamically unfavourable 
and that the optimal Mg concentration (which had a negative formation energy of -0.463 eV) 
had already been attained, Table 2. Furthermore, Mg substitution into the crystalline calcium 
phosphate phase hydroxyapatite was shown to be energetically unstable, with a positive 
formation energy of +1.747 eV. This demonstrated that at our synthetic composition, the 
amorphous phase would retain its integrity and effectively prevent crystallisation.  
Consistent with our prior in vivo findings
17
, analysis by high angle annular dark field 
scanning transmission electron microscopy (HAADF-STEM; Figure 2, C-E), and then 3D-
reconstruction of protein-loaded synthetic AMCP clusters (Figure 2, F-I) confirmed the 
porous nature of the particles (pore average size of 1-3 nm).  Under the synthetic conditions 
described above ~ 50% of the 500 μg/ml BSA protein was trapped by AMCP whether 
peptidoglycan was present or not (Figure 3a). About 60% of the 50 μg/ml peptidoglycan was 
also trapped (Figure 3, A) such that, overall, the AMCP construct contained 10% protein and 
1% bacterial peptidoglycan by weight (Table 1). The synthetic AMCP nanoparticles were 
versatile and non-specific in the trapping of organic matter since other proteins (e.g., avidin) 
and molecules such as bacterial lipopolysaccharide (LPS), soluble starch (a complex 
carbohydrate) and retinoic acid (vitamin A–derived compound) were all efficiently 
incorporated, from 20-90% of their original solution concentration (Figure 3, B). To facilitate 
later work that required the use of fluorescent cargo for cellular experiments, we also show 
that fluorescently-labelled macromolecules (Alexa Fluor 555 BSA and Texas Red OVA) 
were trapped by AMCP (Figure S2, A). It is noteworthy that the presence of Mg not only 
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provided stability of the particle’s phase but it also promoted a greater association with 
proteins than regular amorphous calcium phosphate free of Mg (i.e. ACP; Figure S2, B-C). 
To support the idea that the internal porosity observed by STEM is a result of the AMCP 
mineral templating around much smaller macromolecular components during synthesis, we 
undertook further studies with an electron dense macromolecule to enable visualisation by 
electron microscopy. Synthetic AMCP nanoparticles were therefore prepared in the presence 
of ultra-fine iron (III) oxohydroxide nanoparticles 
24
 (5-10 nm diameter). Electron 
microscopy imaging (Figure 3, C-D), tomographic reconstruction (Figure 3, E-H), models 
with increasing transparency views (Figure 3, I-L) all confirmed that the fine nano-iron 
particles were densely incorporated within the synthetic AMCP. 
Biological properties 
We next sought to investigate, in vitro, whether synthetic AMCP nanoparticles would 
modulate cellular responses and we took a step-wise approach where AMCP uptake, cargo 
delivery, toxicity, inflammasome activation and gene expression modulation were 
investigated.  
By means of calcein staining and flow imaging analyses we confirmed that synthetic AMCP 
nanoparticles were efficiently and selectively taken up by APCs in culture, namely CD14
+
 
monocytes from a mixed cell culture of peripheral blood mononuclear cells (PBMC; Figure 
4, A-B, p = 0.01). To then examine protein carriage by AMCP and delivery into cells, we 
used BSA fluorescently tagged with Alexa Fluor 555 to track the incidence of protein within 
cells of the monocyte lineage in conjunction with fluorescently labelled AMCP. Twenty-two 
percent (± 7; SD) of monocytes within PBMC were positive for AMCP and identified as 
calcein positive CD14
+
 cells. The addition of fluorescent protein during AMCP synthesis did 
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not alter the percentage of cells displaying calcein positivity (Figure 4, C-D). Of this AMCP 
(calcein) positive fraction of CD14
+
 cells, over half were also Alexa Fluor 555 bright 
indicating the presence of BSA protein in addition to AMCP (data not shown). These double 
positive cells were then further assessed for the spatial similarity of the 2 fluorescent markers. 
This analysis suggested that AMCP and protein fluorescence displayed a high degree of 
similarity in 60% (± 7; SD) of the CD14
+
 cells positive for both fluorescent markers (Figure 
4, E-F). Examples of high and low similarity images are shown in Figure 4, G. Overall these 
data not only corroborate the association of AMCP with macromolecules but also 
demonstrate carriage and delivery of protein into CD14
+
 cells by AMCP as indicated by the 
co-incidence of the respective fluorescent markers within cells. 
We then used adherent macrophages (differentiated THP-1) to study AMCP dissolution in 
real time using live imaging (see supplementary methods). This showed avid uptake of 
calcein-labelled AMCP (Figure 5, B) while no fluorescence could be observed after 
incubation with calcein alone (Figure 5, A). In cells, the count of discrete, punctate green-
fluorescent objects decreased gradually over time (Figure 5, C) and became undetectable 18 
hours post-stimulation hence confirming that synthetic AMCP nanoparticles were 
dissolved/digested (Figure 5, D; effect of time p <0.0001). Loss of calcein fluorescence was 
not observed when calcein solutions were incubated alone (Figure 5, E), consistent with 
intracellular dissolution of ‘particulate calcein’ rather than dye quenching over time (Figure 
5, E). Indeed, since AMCP nanoparticles were transported to CD107
+
 (LAMP1
+ve
) lysosomal 
compartments (Figure 5, F) of peripheral blood monocytes, the time-dependent decline of the 
fluorescence is consistent with intracellular particle digestion in the acidic environment of 
endo-lysosomes
26-28
. 
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Next we investigated APC responses to protein-loaded nanomineral AMCP with and without 
peptidoglycan. 
Canonical activation of the inflammasome and IL-1β production usually require a two-signal 
process 
29
 but may also arise from lysosomal disruption preceding cell death which can be 
induced, for example, by the gorging of calcium phosphate nanoparticles
30
. To demonstrate 
the role of synthetic AMCP in inflammasome activation, blood-derived mononuclear cells 
were first subjected to vehicle or LPS pre-stimulation to induce pro-IL1β synthesis, and IL-
1β production was measured 21 hrs after a 3 hour-challenge with synthetic AMCP. Under 
conditions where artefactual activation of the inflammasome is avoided 
30
, it was evident that 
synthetic AMCP, in contrast to crude peptidoglycan (Figure 6, A; P<0.01) and to some 
calcium phosphate crystals 
31-32
, did not activate the inflammasome platform as the levels of 
secreted IL-1β were similar to those observed for the control (i.e. vehicle alone; Figure 6, A). 
Moreover, cellular uptake of synthetic AMCP was innocuous even under prolonged 
experimental conditions where particle gorging may ensue 
30
 (i.e., following 24 hour 
exposure in culture) as cell viability was not affected in primary cells or THP-1 cells (p = 
0.0003 versus apatitic calcium phosphate-challenged cells; Figure 6, B).  
Having observed neither toxicity nor inflammasome activation by the AMCP nanomineral 
under the tested conditions, we next considered what cellular responses did ensue. We looked 
at responses across the whole genome and, remarkably, found that cells challenged with 
protein-loaded synthetic AMCP nanoparticles displayed exactly the same transcriptomic 
‘signature’ to that of unchallenged cells (Figure 6, C). Since peptidoglycan is the inferred 
signalling molecule in the nanomineral-antigen-peptidoglycan pathway, we next sought how 
synthetic AMCP nanoparticles, loaded with both protein and peptidoglycan, affected 
peptidoglycan ‘signalling’. Masking (i.e., down regulation of the cell’s sensitivity to 
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peptidoglycan) or enhancing recognition were both possibilities so, again, we used whole 
genome transcriptomics as a read-out. Whether delivered in soluble form or as cargo within 
the synthetic AMCP nanoparticles, gene regulation in response to ultra-pure E.Coli 
peptidoglycan was precisely the same (i.e., no gene regulation differed by more than the ‘cut-
off’ of 2-fold; Figure 6, D).  
These findings also showed therefore that, PD-L1, the likely target for peptidoglycan 
signalling in the AMCP nanomineral pathway in vivo 
17
, was equally upregulated whether 
peptidoglycan from E. Coli was delivered alone or as cargo (Figure S3). Given that 
peptidoglycan also derives from Gram
+
 bacteria, we finally confirmed that peptidoglycan 
from Gram
+
 S. Aureus, alone or delivered by the AMCP nanomineral, similarly imprinted 
PD-L1 expression on APCs in in vitro cell culture (Figure 7).  
Together, our data demonstrate that in vitro synthetic AMCP nanoparticles mimic their in 
vivo endogenous counterparts in terms of size (Figure 8, A), elemental composition (Figure 8, 
B), and in the trapping of macromolecules (cargo) allowing effective delivery to cells (Figure 
8, C). Moreover we show that the in vivo reported biological function of PD-L1 up-
regulation, driven by the peptidoglycan cargo
17, 33
, is conserved in vitro (Figure 8, D). 
Discussion  
Constitutive formation of AMCP nanoparticles, typically 75-150 nm in diameter, is a normal 
physiological and conserved process that occurs in the gastrointestinal tract of different 
mammalian species
17
. During its formation, the AMCP nanomineral co-associates with 
macromolecules that are present in the lumen and, like other non-biological particles of 
similar sizes
34
, efficiently crosses the epithelial barrier via M cells of the Peyer’s patches17. 
The cargo-containing nanomineral transiently accumulates in APCs underlying the 
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epithelium where mineral digestion and release of the cargo occur
17
. This process likely 
promotes immuno-surveillance of luminal antigens. In this work, we aimed to produce 
synthetics forms of these particles with a view to start trying to establish some of their 
biological relevance in in vitro investigations.  
Our findings demonstrate that synthetic AMCP nanoparticles act as effective but entirely 
silent delivery platforms both in their own right and also in terms of cellular responses to 
peptidoglycan. For two reasons these findings are surprising. Firstly, whilst failure to activate 
the inflammasome by apatitic calcium phosphate nanoparticles has been reported recently by 
us, a lack of cell death following gorging (i.e. up to 24 hr exposure to synthetic AMCP 
nanomineral) was unexpected based upon these prior studies
30
. It is possible that the cargo 
contained within the AMCP confers protection against cell death by slowing down lysosomal 
dissolution of the nanoparticles, as recently demonstrated for fetuin and calcium phosphate in 
human vascular smooth muscle cells
35
, ensuring cell safety of the entire conjugate. Secondly, 
nanoparticles, including nano forms of calcium phosphates, have been widely used as 
adjuvants to enhance immunogenicity to protein antigens and microbial associated molecular 
patterns
36-38
, again unlike the role of the particles in this study. The anticipated in vivo 
function of endogenously-formed AMCP may require this inert (silent-delivery) nature of the 
cargo-bearing particles because the default setting for gastrointestinal immune cells is one of 
hyporesponsiveness and tolerance towards non-self antigens
39-40
. Whilst the AMCP is inert, 
its cargo (notably peptidoglycan) appears to actively promote tolerance in the normal gut by 
up-regulating the co-regulatory molecule, PD-L1, on APCs  that are recipients of endogenous 
cargo-bearing AMCP 
17, 33
. However, this is not the case in Crohn’s disease41. We have 
recently shown that APCs of the AMCP pathway display a selective failure in expression of 
PD-L1 in this disorder
41
 and hence hypothesised that this may lead to a loss of tolerance 
towards luminal contents- a hallmark of the disease
42
. It is therefore likely that, under normal 
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circumstances, the mammalian gut immune system has evolved to use an endogenous carrier 
of luminal macromolecules that can (a) trap luminal proteins and microbial associated 
molecular patterns effectively (b) allow transport to APCs whilst protecting the cargo from 
enzymatic degradation en route and, pertinent to the findings here, (c) not promote cellular 
reactivity in a naturally hyporesponsive environment.  
In summary, the synthesis of AMCP has been inspired by its presence in nature and it may be 
a rather special nanomaterial that does not, acutely, promote cell activity following its uptake 
nor shield the cell signalling of its cargo. Further work should now consider AMCP for the 
delivery of immunogenic protein (with and without bacterial fragments) and see how this 
might influence cell mediated immunity. This would further inform on function and perhaps 
provide a novel therapeutic nano-carrier, especially for impacting tolerance in the gut.  
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Appendix A: Supplementary methods and data. 
Figure legends: 
Figure 1.  Sizing and TEM morphology of synthetic AMCP nanomineral from cell 
culture medium: A-B- Nanoparticle tracking analyses of synthetic AMCP particles that 
were prepared in the presence of bovine serum albumin (BSA) with (red columns) and 
without bacterial peptidoglycan (sPg; black columns), either (A) in cell culture medium (37 
°C) immediately after suspension or (B) following 3 hrs incubation (37 °C) in cell culture 
medium. Size distributions are shown as average of three independent experiments and are 
displayed as cumulative particle number (E6/ml) per size interval (i.e. every 10 nm). 
Supplementary table 1 provides additional data. C-D- Morphologic characterisation of the 
above particles by TEM after 1hr incubation of the particles in cell culture medium at 37 °C. 
Scale bars – 100 nm. Detailed STEM analysis of the precipitated and washed powder prior to 
addition to cell culture medium is shown in Figure 2. E- Energy optimised structure of Mg-
substituted calcium phosphate cluster, which represents a precursor to the larger particles. 
The central Mg substitution is in the most favourable position as calculated by Density 
Functional Theory. The composition of the cluster reflects analytical results of the larger 
particles by X-ray microanalysis. Hydrogen was included for charge compensation. Calcium 
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is shown in green, oxygen in red, phosphorus in purple, magnesium in yellow and hydrogen 
in pink. 
Figure 2. STEM characterisation of synthetic AMCP nanoparticles: A- High angle 
annular dark-field STEM image of synthetic AMCP particle clusters (Scale bar 20 nm) and 
B- example elemental composition by energy dispersive X-ray microanalysis. C-E- A series 
of orthoslices of a synthetic AMCP particle (Scale bar 20 nm) revealing a detailed inner 
structure (F-I) from the reconstructed volume (F) by means of several orthoslices through the 
XY plan and (G-I) transparency views through the YZ, XZ and XY orientations, 
respectively. 
Figure 3. Trapping of macromolecules by the synthetic AMCP nanomineral: A- 
Percentage incorporation, from the original solution, of protein (BSA; left hand-side and 
middle column) and bacterial peptidoglycan (sPg, right hand-side column) in synthetic 
AMCP prepared in the presence of BSA with (hatched columns) and without peptidoglycan 
(white column), and as determined by the Bradford protein and periodic acid Schiff assay, 
respectively (n= 5-6 experiments ± SD). B- Overall percentage incorporation of protein 
(white circles are BSA and red circles are avidin), bacterial fragments (white squares are sPg 
and red squares are LPS) and other macromolecules (white triangles are soluble starch and 
red squares are retinoic acid) in synthetic AMCP. C-D- TEM of synthetic AMCP 
nanoparticles prepared in the presence of iron oxide nanoparticles showing fine nano-iron 
particles densely incorporated into the AMCP structure. Scale bars 100 nm and 50 nm 
respectively. E-H STEM-tomography data of synthetic AMCP, containing fine nano-iron 
particles, from the reconstructed volume (e) by means of several orthoslices though the XY 
plane and (F-H) showing individual slices and finally (I-L) the 3D reconstruction in differing 
views. The iron oxide nanoparticles are shown in red in I-L. 
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Figure 4. In vitro uptake of synthetic AMCP nanoparticles and delivery of cargo into 
cells: A- Flow cytometric quantitation of cells that have taken up synthetic calcein-labelled 
AMCP within the lymphocyte and monocyte gates (n = 3 ± SD). B- Image Stream analyses 
of PBMC that were incubated with synthetic calcein-labelled AMCP displaying the monocyte 
population that have taken up AMCP (n = 4 ± SD). **p=0.01 versus vehicle. C. Example of 
Image Stream dot plot from one donor showing gated CD14
+
 cells positive for the AMCP 
label calcein, and D. graph showing the average percentage of CD14
+
 cells positive for 
calcein after 3 h incubation with AMCP particles synthesized with or without Af555 labelled 
BSA. E. Example histogram plot of calcein/Af555-BSA similarity scores of double positive 
cells for 1 subject after 3 h incubation, showing hi and low similarity regions. F. Pie Chart 
visualising percentage of CD14
+
 (calcein/Af555 double positive) cells falling within hi 
(yellow) and low (green) similarity regions: data shown is the average of experiments 
performed on cells from 3 subjects. G. Example cell images of calcein/Af555 double positive 
CD14 cells falling within the hi and low similarity gate. 
Figure 5.  Uptake, lysosomal delivery and dissolution of synthetic AMCP nanoparticles 
PMA-differentiated THP-1 macrophages were incubated with calcein-labelled AMCP for 3 
hrs and then washed to remove residual AMCP particles. Images were then acquired every 2 
hr by the Incucyte
TM
. A-C Representative images from the green channel (right hand-side) 
and overlay images of phase contrast and green fluorescence (left hand-side) that were 
acquired one hour-post stimulation with A. TCM, B. AMCP and C. 11 hours-post stimulation 
with AMCP (10x magnification). D. Particle count, as quantified by the IncucyteZOOM 
software, was normalised against cell confluence, and is expressed as percent of values 
obtained in the first scan. X-axis indicates monitoring time by live cell imaging post-
stimulation, i.e., 0 hr represents the first scan (i.e. straight after 3 hours stimulation with 
calcein-labelled AMCP). Data are presented as mean ± SD (n=5, obtained from two 
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independent experiments performed in technical replicates). E. Mean green fluorescence 
intensity of soluble calcein added at indicated concentrations to tissue culture medium 
(acellular environment) and measured by the Incucyte
TM
. Dye quenching was induced by the 
addition of 1 mM iron as iron hydroxide adipate tartrate. Data are shown as connecting 
curves for the mean of technical triplicates from one experiment. F. Image Stream summary 
of internalised synthetic calcein-labelled AMCP in peripheral blood monocytes (left column) 
that were concomitantly positive for the lysosomal marker D107 (Right column; n= 4 ± 
SD). 
Figure 6. In vitro gene and cellular responses to AMCP nanoparticles: A- Lack of 
inflammasome activation by synthetic AMCP as measured by IL-1β secretion following LPS 
pre-stimulation (10 ng/ml) and subsequent challenge with vehicle (TCM; black circle) or 
synthetic AMCP (red circle) or with bacterial peptidoglycan (grey circle). Positive control 
crude peptidoglycan shown in open grey circles.  **p<0.01 and ***P<0.001 versus vehicle 
(n=6). B- Cell viability was assessed by flow cytometry in monocytes (white column, n= 5 ± 
SD) and by the LDH assay in THP1 cells (red column, duplicates). ***P=0.0003 versus 
AMCP (red column). C- Average log2 expression values of genes, after 3 h exposure to 
synthetic AMCP, correlated against those of vehicle control treatment (n=7). D- Average log2 
fold changes of genes significantly affected (p < 0.01, n=7) by 3 hr treatment with synthetic 
AMCP/sPg nanoparticles or with sPg alone (both versus vehicle control) and plotted against 
each other. Theoretical line of perfect correlation (black line) and borders corresponding to 
twofold up- and down-regulation (red lines) were overlaid on the data in both c and d. 
Figure 7. Peptidoglycan cargo of AMCP nanomineral upregulates cellular PD-L1 
expression: A – Cell surface PD-L1 is upregulated in antigen presenting cells by 
peptidoglycan (Pg) and by Pg delivered in synthetic nanomineral particles (AMCP-Pg) that 
were visualised by pre-labelling with calcein. B – Example flow cytometric plots of CD11b+ 
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pre-gated cells showing dual calcein/PD-L1 positivity upon stimulation with vehicle 
(control), peptidoglycan (Pg) or calcein-tagged Pg-bearing synthetic nanomineral particles 
(AMCP-Pg). C– Representative histograms showing PD-L1 positivity of CD11b+ gated cells 
following exposure to protein-bearing synthetic nanomineral particles (AMCP), 
peptidoglycan (Pg) or Pg-bearing nanomineral particles (AMCP-Pg). D – Mean ± SEM  PD-
L1
+
 CD11b
+
 cells within the monocyte gate of peripheral blood mononuclear cell populations 
derived from 7 healthy donors following exposure to protein-bearing synthetic nanomineral 
particles (AMCP), peptidoglycan (Pg) or Pg-bearing synthetic nanomineral particles (AMCP-
Pg). * asterisked data are not significantly different whilst p < 10
-6
 for asterisked versus non-
asterisked data. 
Figure 8. Comparisons of in vitro synthetic AMCP to the in vivo AMCP nanomineral 
The upper panel displays the in vivo characteristics of AMCP and has been reproduced with 
permission from Nature Nanotechnology (adapted from Powell JJ et al
17
). The lower panel is 
a summary of the characteristics of in vitro generated AMCP in this work.  
A- High angle annular dark-field STEM image of AMCP particle clusters. B- Elemental 
composition by energy dispersive X-ray microanalysis. C-D- Upper panels: C-In vivo 
confocal micrographs showing a 3D stack, with Huygens MLE deconvolution, visualised 
with calcein staining for the endogenous nanomineral (green) and with antibody staining for 
ovalbumin (red) and D-PD-L1 (red) expression in calcein positive (green) cells. C-D- The 
lower panels displays the in vitro equivalence and shows the percentage of fluorescent 
protein (red column for BSA555 and red dashed column for Texas Red OVA) present within 
AMCP, the uptake of synthetic AMCP (green) into PD-L1
+
 cells (yellow) by Image Stream 
and the resulting PD-L1 up-regulation (green histogram) by Flow cytometry. 
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Graphical Abstract 
Amorphous magnesium-substituted calcium phosphate (AMCP) nanoparticles, which form 
naturally in the mammalian gut, may play an important role in immune surveillance by 
promoting the delivery of luminal macromolecules to mucosal immune cells. To further 
probe this constitutive phenomenon, we set out to develop a synthetic mimetic generating in 
vitro amorphous calcium phosphate nanoparticles similar to their in vivo counterparts.  
Resulting synthetic particles were of the right size (75-150 nm), phase (amorphous) and 
composition (magnesium-substituted calcium phosphate) and trapped macromolecules 
effectively delivering them to antigen presenting cells without adverse effects. The silent 
delivery of macromolecules by synthetic AMCP informs on their in vivo role and could be 
exploited as a safe platform for antigen delivery. 
 
 
 
